Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Gralise® for Chronic Pelvic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and older~* English speaking~* able to give consent~* willing to use electronic diary during entire length of the study~* has 'chronic' pelvic pain~* Meets one of the following diagnostic criteria for one of the following: Irritable Bowel Syndrome (IBS) Ulcerative Colitis (UC), Interstitial Cystitis (IC), and Prostatitis~Exclusion Criteria:~* allergic to gabapentin or inactive ingredients~* taking gabapentinoids (i.e. gabapentin or pre-gabalin)~* with severe or unmanaged psychiatric disturbance (at PI discretion)~* with severe ongoing or unaddressed medical conditions (esp. Renal or Hepatic disease, uncontrolled hypertension), rheumatologic disease, narrow angle glaucoma, hyponatremia, clotting disorders, uncontrolled seizure disorder or urinary retention.~* who plan to change their therapeutic regimen during the course of the trial (e.g. start physical therapy, massage, medications, injections, etc.)~* with acute pain~Female subjects:~* pregnant or plan to become pregnant~* gave birth within the last 6 months~* breastfeeding~* episodic visceral pain (e.g. endometriosis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo then Gralise (Type: PLACEBO_COMPARATOR): Subjects may receive a pill with no medicine (placebo) for phase 1. Subject washout, then cross over to Gralise in Phase 2.
- Gralise then Placebo (Type: ACTIVE_COMPARATOR): Subjects recieve Gralise (a long acting gabapentinoid) for phase 1.Subject washout, then cross over to placebo in Phase 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).